NASDAQ : RANI
Rani Therapeutics Holdings, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.6054 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 84.39M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 81.00M |
| Enterprise Value | 31.16M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 115.42M |
| Shares Outstanding | 139.40M |
| Shares Change (YoY) | +321.63% |
| Shares Change (QoQ) | +3.98% |
| Owned by Insiders (%) | 3.75% |
| Owned by Institutions (%) | 25.29% |
| Float | 82.32M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.86 |
| Forward PS | 28.85 |
| PB Ratio | 1.69 |
| P/TBV Ratio | 2.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 6.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.31 |
| Quick Ratio | 5.23 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -28.22 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -172.15% |
| Return on Assets (ROA) | -52.99% |
| Return on Invested Capital (ROIC) | -64.38% |
| Return on Capital Employed (ROCE) | -65.65% |
| Weighted Average Cost of Capital (WACC) | 8.90% |
| Revenue Per Employee | $68,690 |
| Profits Per Employee | -$424,521 |
| Employee Count | 71 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.71 |
| 52-Week Price Change | -73.59% |
| 50-Day Moving Average | 0.76 |
| 200-Day Moving Average | 0.93 |
| Relative Strength Index (RSI) | 30.38 |
| Average Volume (20 Days) | 517,665 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8.16M |
| Short Previous Month | 7.25M |
| Short % of Shares Out | 5.85% |
| Short % of Float | 9.91% |
| Short Ratio (days to cover) | 13.33 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 4.88M |
| Gross Profit | 4.88M |
| Operating Income | -32.96M |
| Pretax Income | -33.42M |
| Net Income | -30.14M |
| EBITDA | -32.24M |
| EBIT | -32.96M |
| Loss Per Share | -$0.22 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 53.39M |
| Total Debt | 3.55M |
| Net Cash | 49.84M |
| Net Cash Per Share | $0.36 |
| Equity (Book Value) | 47.99M |
| Book Value Per Share | 0.35 |
| Working Capital | 45.89M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -20.29M |
| Capital Expenditures | -47,000 |
| Depreciation & Amortization | 722,000 |
| Net Borrowing | -13.22M |
| Free Cash Flow | -20.34M |
| FCF Per Share | -$0.15 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -675.80% |
| Pretax Margin | -685.34% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -321.63% |
| Shareholder Yield | -321.63% |
| Earnings Yield | -37.41% |
| FCF Yield | -24.73% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $7.20 |
| Price Target Difference | 1,139.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 104.21% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.15 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |